IceCure Medical Ltd. (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
Company profile
Ticker
ICCM
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
15 Apr 24
6-K
IceCure Medical Reports Final ICE3 Breast Cancer
15 Apr 24
6-K
Report of Foreign Private Issuer
3 Apr 24
20-F
2023 FY
Annual report (foreign)
3 Apr 24
6-K
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
2 Apr 24
6-K
Report of Foreign Private Issuer
19 Mar 24
6-K
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
12 Mar 24
6-K
Report of Foreign Private Issuer
4 Mar 24
6-K
Study Using IceCure’s ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
26 Feb 24
6-K
IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of previous expectation
30 Jan 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
53.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 5 |
Closed positions | 2 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 169.84 mm |
Total shares | 24.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Epoch Partner Investments | 24.05 mm | $31.75 mm |
Alpha Capital Anstalt | 290.38 k | $0.00 |
Boothbay Fund Management | 40.00 k | $46.40 mm |
BAC Bank Of America | 32.30 k | $37.47 mm |
Renaissance Technologies | 18.90 k | $22.00 k |
BCS Barclays | 18.10 k | $21.00 k |
Susquehanna International | 16.26 k | $18.86 mm |
Two Sigma Securities | 13.83 k | $16.04 mm |
AE Wealth Management | 10.00 k | $11.60 mm |
Advisor | 5.67 k | $6.58 mm |
News
HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
16 Apr 24
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results; Data Submitted To FDA Requesting Marketing Authorization To Treat Early-Stage Breast Cancer
15 Apr 24
HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
4 Apr 24
Icecure Medical Q4 EPS $(0.07), Inline, Sales $1.25M Beat $1.17M Estimate
3 Apr 24
Icecure Medical FY EPS $(0.32), Inline, Sales $3.23M Beat $3.14M Estimate
3 Apr 24
Press releases
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
15 Apr 24
Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery
12 Apr 24
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
3 Apr 24
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
2 Apr 24
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
27 Mar 24